BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 35802372)

  • 1. Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Thietart S; Karras A; Augusto JF; Philipponnet C; Carron PL; Delbrel X; Mesbah R; Blaison G; Duffau P; El Karoui K; Smets P; London J; Mouthon L; Guillevin L; Terrier B; Puéchal X;
    JAMA Netw Open; 2022 Jul; 5(7):e2220925. PubMed ID: 35802372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab treatment in ANCA-associated vasculitis patients: outcomes of a real-life experience from an observational cohort.
    Carranza-Enríquez F; Meade-Aguilar JA; Hinojosa-Azaola A
    Clin Rheumatol; 2022 Sep; 41(9):2809-2816. PubMed ID: 35507201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
    Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
    JAMA; 2021 Jun; 325(21):2178-2187. PubMed ID: 34061144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
    Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.
    Smith RM; Jones RB; Specks U; Bond S; Nodale M; Aljayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani RA; Makino H; McAlear CA; Monach P; Moreland LW; Mynard K; Nachman P; Pagnoux C; Pearce F; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Weisman MH; Wroe C; Merkel PA; Jayne D; ;
    Ann Rheum Dis; 2020 Sep; 79(9):1243-1249. PubMed ID: 32581088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: Effectiveness and safety in the first 6 months.
    Nagasaka K; Amano K; Dobashi H; Nagafuchi H; Sada KE; Komagata Y; Yamamura M; Kato M; Endo T; Nakaya I; Takeuchi T; Murakawa Y; Sugihara T; Saito M; Hayashi T; Furuta S; Tamura N; Karasawa K; Banno S; Endo S; Majima M; Kaname S; Arimura Y; Harigai M
    Mod Rheumatol; 2023 Nov; 33(6):1117-1124. PubMed ID: 36478050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.
    Charles P; Perrodeau É; Samson M; Bonnotte B; Néel A; Agard C; Huart A; Karras A; Lifermann F; Godmer P; Cohen P; Hanrotel-Saliou C; Martin-Silva N; Pugnet G; Maurier F; Sibilia J; Carron PL; Gobert P; Meaux-Ruault N; Le Gallou T; Vinzio S; Viallard JF; Hachulla E; Vinter C; Puéchal X; Terrier B; Ravaud P; Mouthon L; Guillevin L;
    Ann Intern Med; 2020 Aug; 173(3):179-187. PubMed ID: 32479166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience.
    Mittal S; Naidu GSRSNK; Jha S; Rathi M; Nada R; Minz RW; Sharma K; Dhir V; Jain S; Sharma A
    Clin Rheumatol; 2021 Feb; 40(2):645-651. PubMed ID: 32656662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
    Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
    Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
    Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
    Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial.
    Zonozi R; Cortazar FB; Jeyabalan A; Sauvage G; Nithagon P; Huizenga NR; Rosenthal JM; Sipilief A; Cosgrove K; Laliberte KA; Rhee EP; Pendergraft WF; Niles JL
    Ann Rheum Dis; 2024 Feb; 83(3):351-359. PubMed ID: 38123922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.
    Puéchal X; Iudici M; Perrodeau E; Bonnotte B; Lifermann F; Le Gallou T; Karras A; Blanchard-Delaunay C; Quéméneur T; Aouba A; Aumaître O; Cottin V; Hamidou M; Ruivard M; Cohen P; Mouthon L; Guillevin L; Ravaud P; Porcher R; Terrier B;
    JAMA Netw Open; 2022 Nov; 5(11):e2243799. PubMed ID: 36441554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.
    Jones RB; Ferraro AJ; Chaudhry AN; Brogan P; Salama AD; Smith KG; Savage CO; Jayne DR
    Arthritis Rheum; 2009 Jul; 60(7):2156-68. PubMed ID: 19565480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How best to manage relapse and remission in ANCA-associated vasculitis.
    Puéchal X; Guillevin L
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1135-1143. PubMed ID: 36102147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study.
    Thietart S; Beinse G; Smets P; Karras A; Philipponnet C; Augusto JF; El Karoui K; Mesbah R; Titeca-Beauport D; Hamidou M; Carron PL; Maurier F; Sacre K; Cohen P; Liozon E; Blanchard-Delaunay C; Kostianovsky A; Pagnoux C; Mouthon L; Guillevin L; Terrier B; Puéchal X;
    J Intern Med; 2022 Mar; 291(3):350-363. PubMed ID: 34755398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
    Watanabe R; Oshima M; Nishioka N; Sada KE; Nagasaka K; Akiyama M; Ando T; Higuchi T; Inoue Y; Kida T; Mutoh T; Nakabayashi A; Onishi A; Sakai R; Waki D; Yamada Y; Yajima N; Tamura N; Kaname S; Harigai M
    Mod Rheumatol; 2023 Aug; 33(5):982-989. PubMed ID: 36112482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.